Safety and antitumor activity of recombinant soluble Apo2 ligand

Journal of Clinical Investigation

Volumn 104, Issue 2, 1999, Pages 155-162

  Ashkenazi, Avi ^a   Pai, Roger C ^a   Fong, Sharon ^a   Leung, Susan ^a   Lawrence, David A ^a   Marsters, Scot A ^a   Blackie, Christine ^a   Chang, Ling ^a   McMurtrey, Amy E ^a   Hebert, Andrea ^a   DeForge, Laura ^a   Koumenis, Iphigenia L ^a   Lewis, Derf ^a   Harris, Louise ^a   Bussiere, Jeanine ^a   Koeppen, Hartmut ^a   Shahrokh, Zahra ^a   Schwall, Ralph H ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; FAS LIGAND; FLUOROURACIL; RECOMBINANT APOLIPOPROTEIN 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SAFETY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

EID: 0032713075     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6926     Document Type: Article

References (38)

1. Jacobson, M.D., Weil, M., and Raff, M.C. 1997. Programmed cell death in animal development. Cell. 88:347-354.
2. Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355-365.
3. Ashkenazi, A., and Dixit, V.M. 1998. Death receptors: signaling and modulation. Science. 281:1305-1308.
4. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331.
5. Tartaglia, L., and Goeddel, D. 1992. Two TNF receptors. Immunol. Today. 13:151-153.
6. Pitti, R.M., et al. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor receptor family. J. Biol. Chem. 271:12687-12690.
7. Wiley, S.R., et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673-682.
8. Pan, G., et al. 1997. The receptor for the cytotoxic ligand TRAIL. Science. 276:111-113.
9. Sheridan, J.P., et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:818-821.
10. Pan, G., et al. 1997. An antagonist decoy receptor and a new death domain-containing receptor for TRAIL. Science. 277:815-818.
11. Walczak, H., et al. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBOJ. 16:5386-5397.
12. Wu, G.S., et al. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:141-143.
13. Schneider, P., et al. 1997. Characterization of two receptors for TRAIL. FEBS Lett. 416:329-334.
14. Chaudhary, P.M., et al. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kB pathway. Immunity. 7:821-830.
15. Screaton, G.R., et al. 1997. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:693-696.
16. Degli-Esposti, M., et al. 1997. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186:1165-1170.
17. Mongkolsapaya, J., et al. 1998. Lymphocyte inhibitor of TRAIL: a new receptor protecting lymphocytes from the death ligand TRAIL. J. Immunol. 160:3-6.
18. Marsters, S.A., et al. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7:1003-1006.
19. Degli-Esposti, M.A., et al. 1997. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:813-820.
20. Pan, G., Ni, J., Yu, G.L., Wei, Y.F., and Dixit, V.M. 1998. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett. 424:41-45.
21. Emery, J.G., et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273:14363-14367.
22. Simonet, W.S., et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309-319.
23. Gruss, H.J., and Dower, S.K. 1995. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 85:3378-3404.
24. Tanaka, M., Itai, T., Adachi, M., and Nagata, S. 1998. Downregulation of Fas ligand by shedding. Nat. Med. 4:31-36.
25. Mariani, S.M., Matiba, B., Armandola, E.A., and Krammer, P.H. 1997. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J. Cell Biol. 137:221-229.
26. Mariani, S., and Krammer, P. 1998. Surface expression of TRAIL/Apo2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28:1492-1498.
27. Marsters, S., et al. 1996. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6:750-752.
28. Walczak, H., et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157-163.
29. Scholtissek, S., and Grosse, F. 1988. A plasmid vector system for the expression of a triprotein consisting of beta-galactosidase, a collagenase recognition site and a foreign gene product. Gene. 62:55-64.
30. Christian, M., et al. 1997. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Semin. Oncol. 24:219-240.
31. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-452.
32. Leichman, C., et al. 1995. Phase II study of fluotouracil and its modulation in advanced colorectal cancer: a southwest oncology group study. J. Clin. Oncol. 13:1303-1311.
33. Vanhoefer, U., et al. 1999. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J. Clin. Oncol. 17:907-913.
34. Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., and Weller, M. 1998. Apo2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 427:124-128.
35. Thomas, W.D., and Hersey, P. 1998. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4Tcell killing of target cells J. Immunol. 161:2195-2200.
36. Mori, S., Murakami-Mori, K., Nakamura, S., Ashkenazi, A., and Bonavida, B. 1999. Sensitization of AIDS-Kaposi's sarcoma cells to Apo2 ligand-induced apoptosis by actinomycin D. J. Immunol. 162:5616-5623.
37. Snell, V., et al. 1997. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol. 99:618-624.
38. Marsters, S., et al. 1996. Apo3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr. Biol. 6:1669-1676.